Conclusion Non-heterogeneous HER2 IHC 2+ tumours tend to be HER2-amplified. Adding the percentage of cells with HER2 >6 copies to the average HER2/CEP17 ratio may facilitate assessment of amplification status in ISH-equivocal cases. The proportion of cells with HER2/CEP17 >= 2.0 contributes ...
由于HER2基因扩增导致细胞膜上HER2受体明显过表达,使用经临床验证的抗体和基于细胞膜表面受体表达强度和完整性的评分系统进行免疫组织化学(IHC)检测,构成了区分HER2阴性(IHC评分0/1+)和阳性(IHC评分3+)肿瘤的筛选方法,同时能够识别出HER2蛋白完整但仅中度表达的肿瘤(IHC评分2+,待明确),而这需要从基因状态方面进一步研...
‘equivocal’ to characterize HER2 studies that are 2+ by IHC and/or show HER2/chromosome 17 ratios of between 1.8 and 2.2 by FISH; (d) requirements for laboratories to validate HER2 assays, generally through the cross-testing of cases with another HER2 methodology, with laboratories required ...
An equivocal result represented by score 2+, requires further tests for confirming the presence or absence of HER2 gene amplification and this is achieved using the second method, in situ hybridisation or most commonly fluorescent in situ hybridisation (FISH). The most recent guidelines produced by...
HER2 FISH is reported as amplified (HER/ CEP17 ratio 42.2), equivocal (ratio 1.8–2.2), or negative (ratio o1.8). A number of factors appear to improve concor- dance levels between HER2 assessment by IHC and FISH. Image analysis has been demonstrated to improve interobserver variability ...
RESULTS: Among the 1 780 IHC HER2 (2+ ) invasive breast cancers, the number of HER2 positive, equivocal and negative case were 310(17.41%), 66(3.71%)and 1 404(78.88%) respectively, basing on the 2007 guidelines; w...
equivocalhuman epidermal growth factor receptor 2insitu hybridizationoncotype DXpolymerase chain reactionIn breast cancer, human epidermal growth factor receptor 2 (HER2) status is determined by immunohistochemistry (IHC) and/or insitu hybridization. Oncotype DX also reports HER2 status by an rt-PCR-...
For cases with equivocal IHC results (2+), additional testing using fluorescence in situ hybridization (FISH) or silver in situ hybridization (SISH) is recommended. These tests detect the amplification of the Her2 gene, which is indicative of Her2 overexpression. A positive result on FISH or SI...
HER2, ER, PR, and Ki-67 status were determined by IHC, with equivocal HER2 cases assessed by in situ hybridization. Survival outcomes were estimated using the Kaplan鈥揗eier method, with Cox regression identifying predictors of survival. Results Among 43 cases, 31 (70.5%) were HER2-low, 6 ...
ImmunoMembrane DIA using digital photomicrographs and WSI showed almost perfect agreement. In conclusion, digital image analysis by ImmunoMembrane can help to resolve a majority of equivocal 2+ cases in HER2 IHC, which reduces the need for ISH testing. 展开 ...